Cancer Genetics and Epigenetics 2017, Vol.5, No.1, 1
-
5
4
widely used in clinical practice. Pertuzumab add to Trastuzumab andpaclitaxel is the first-line treatment of
metastatic breast cancer to Her - 2 positive patients (Swain et al., 2014).
Acknowledgment
This work was supported by the Science Innovation Project (201613) and Special Fund for Excellent Academic Leader of Harbin
(2015RAXYJ051).
References
Budach W., Matuschek C., and Bölke E., 2015, Erratum to: DEGRO practical guidelines for radiotherapy of breast cancer V: Therapy for locally advanced and
inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases, Strahlentherapie and Onkologie, 191(8): 623-633
Braunstein L.Z., Brock J.E., Chen Y.H., Truong L., Russo A.L., Arvold N.D., and Harris J.R., 2015, Invasive lobular carcinoma of the breast: local recurrence
after breast-conserving therapy by subtype approximation and surgical margin, Breast Cancer Research and Treatment, 149(2): 555-564
PMid:25604797
Christinat A., Lascio S.D., and Pagani O., 2013, Hormonal therapies in young breast cancer patients: when, what and for how long?, Journal of Thoracic
Disease, 5(S1): 36-46
Dabbs D.J., Schnitt S.J., Geyer F.C., Weigelt B., Baehner F.L., Decker T., Eusebi V., Fox S.B., Ichihara S., Lakhani S.R., Palacios J., Rakha E., Richardson A.L.,
Schmitt F.C., Tan P.H., Tse G.M., Vincent-Salomon A., Ellis I.O., Badve S., and Reis-Filho J.S., 2013, Lobular neoplasia of the breast revisited with
emphasis on the role of e-cadherin immunohistochemistry, The American Journal of Surgical Pathology, 37(7): 1-11
PMid:23759937
Davies C., Pan H., Godwin J., G., Raina V., Abraham M., Alencar M.V.H., Badran A., Bonfill X., Bradbury J., Clarke M., Collins R., Davis S.R., Delmestri A.,
Forbes J.F., Haddad P., Houetal M.F., Inbar M., Khaled H., Kielanowska J., Kwan W.H., Mathew B.S., Mittra I., Müller B., Nicolucci A., Peralta O.,
Pernas F., Petruzelka L., Pienkowski T., Radhika R., Rajan B., Rubach M.T., Tort S., Urrútia G., Valentini M., and Peto R., 2013, Long-term effects of
continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised
trial, The Lancet, 381(9869): 805-816
Delpech Y., Coutant C., Hsu L., Barranger E., Iwamoto T., Barcenas C.H., Hortobagyi G.N., Rouzier R., Esteva F.J., and Pusztai L., 2013, Clinical benefit from
neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas, British Journal of Cancer, 108(2): 285-291
PMid:23299541 PMCid:PMC3566807
Engstrøm M.J., Opdahl S., Vatten L.J., Haugen O.A., and Bofin A.M., 2015, Invasive lobular breast cancer: the prognostic impact of histopathological grade,
E-cadherin and molecular subtypes, Histopathology, 66(3): 409-419
PMid: 25283075 PMCid:PMC4329418
Li B.Y., and Li C.G., 2012, The pathological and clinical features of invasive lobular breast carcinoma and comprehensive treatment, China Medical Guide,
10(26): 59-60
Li X., Schwartz M.R., Ro J., Hamilton C.R., Ayala A.G., Truong L.D., and Zhai Q.J., 2014, Diagnostic utility of E-cadherin and P120 catenin cocktail
immunostain in distinguishing DCIS from LCIS, International Journal of Clinical and Experimental Pathology, 7(5): 2551-2557
Menezes G.L., van den Bosch M.A., and Postma E.L., 2013, Invasive ductolobular carcinoma of the breast: spectrum of mammographic, ultrasound and
magnetic resonance imaging findings correlated with proportion of the lobular component, Springer Plus, 2(1): 1-12
PMid:24340243 PMCid:PMC3858590
Nounou M.I., ElAmrawy F., Ahmed N., Abdelraouf K., Goda S., and Syed-Sha-Qhattal H., 2015, Conventional diagnosis and treatment modalities and recent
patents and technologies, Breast Cancer(Auckl), 9(S2): 17-34
PMid:26462242 PMCid:PMC4589089
Oliveira T.M., Elias J.J., Melo A.F., Teixeira S.R., Filho S.C., Gonçalves L.M., Faria F.M., Tiezzi D.G., Andrade J.M., and Muglia V., 2014, Evolving concepts
in breast lobular neoplasia and invasive lobular carcinoma, and their impact on imaging methods, Insights into Imaging, 5(2): 183-194
PMid:24633840 PMCid:PMC3999371
Park J.S., Choi D.H., Huh S.J., Park W., Kim Y., Nam S.J., Lee J.E., and Kil W.H., 2015, Comparison of clinicopathological features and treatment results
between invasive lobular carcinoma and ductal carcinoma of the breast, Journal of Breast Cancer, 18(3): 285-290
PMid:26472980 PMCid:PMC4600694
